We Wouldn't Be Too Quick To Buy Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) Before It Goes Ex-Dividend

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be intrigued to know that Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) is about to go ex-dividend in just 3 days. Typically, the ex-dividend date is two business days before the record date, which is the date on which a company determines the shareholders eligible to receive a dividend. The ex-dividend date is of consequence because whenever a stock is bought or sold, the trade can take two business days or more to settle. This means that investors who purchase Novolog (Pharm-Up 1966)'s shares on or after the 1st of December will not receive the dividend, which will be paid on the 8th of December.

The company's next dividend payment will be ₪0.0195743 per share, and in the last 12 months, the company paid a total of ₪0.039 per share. Looking at the last 12 months of distributions, Novolog (Pharm-Up 1966) has a trailing yield of approximately 3.0% on its current stock price of ₪1.307. Dividends are an important source of income to many shareholders, but the health of the business is crucial to maintaining those dividends. That's why we should always check whether the dividend payments appear sustainable, and if the company is growing.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

If a company pays out more in dividends than it earned, then the dividend might become unsustainable - hardly an ideal situation. Yet cash flows are even more important than profits for assessing a dividend, so we need to see if the company generated enough cash to pay its distribution. Novolog (Pharm-Up 1966) paid out more free cash flow than it generated - 161%, to be precise - last year, which we think is concerningly high. We're curious about why the company paid out more cash than it generated last year, since this can be one of the early signs that a dividend may be unsustainable.

Novolog (Pharm-Up 1966) does have a large net cash position on the balance sheet, which could fund large dividends for a time, if the company so chose. Still, smart investors know that it is better to assess dividends relative to the cash and profit generated by the business. Paying dividends out of cash on the balance sheet is not long-term sustainable.

While Novolog (Pharm-Up 1966)'s dividends were covered by the company's reported profits, cash is somewhat more important, so it's not great to see that the company didn't generate enough cash to pay its dividend. Cash is king, as they say, and were Novolog (Pharm-Up 1966) to repeatedly pay dividends that aren't well covered by cashflow, we would consider this a warning sign.

Check out our latest analysis for Novolog (Pharm-Up 1966)

Click here to see how much of its profit Novolog (Pharm-Up 1966) paid out over the last 12 months.

Have Earnings And Dividends Been Growing?

Companies that aren't growing their earnings can still be valuable, but it is even more important to assess the sustainability of the dividend if it looks like the company will struggle to grow. If earnings decline and the company is forced to cut its dividend, investors could watch the value of their investment go up in smoke. That explains why we're not overly excited about Novolog (Pharm-Up 1966)'s flat earnings over the past five years. It's better than seeing them drop, certainly, but over the long term, all of the best dividend stocks are able to meaningfully grow their earnings per share.

Many investors will assess a company's dividend performance by evaluating how much the dividend payments have changed over time. Novolog (Pharm-Up 1966) has delivered an average of 8.1% per year annual increase in its dividend, based on the past eight years of dividend payments.

Final Takeaway

Should investors buy Novolog (Pharm-Up 1966) for the upcoming dividend? It's disappointing to see earnings per share have fallen slightly, even though Novolog (Pharm-Up 1966) is paying out less than half its income as dividends. It's also paying out an uncomfortably high percentage of its cash flow, which makes us wonder just how sustainable the dividend really is. With the way things are shaping up from a dividend perspective, we'd be inclined to steer clear of Novolog (Pharm-Up 1966).

Although, if you're still interested in Novolog (Pharm-Up 1966) and want to know more, you'll find it very useful to know what risks this stock faces. Be aware that Novolog (Pharm-Up 1966) is showing 3 warning signs in our investment analysis, and 2 of those don't sit too well with us...

Generally, we wouldn't recommend just buying the first dividend stock you see. Here's a curated list of interesting stocks that are strong dividend payers.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.